Piper Sandler analyst David Westenberg lowered the firm’s price target on Idexx Laboratories (IDXX) to $435 from $520 following the company’s earnings report. The firm keeps a Neutral rating on the shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target lowered to $481 from $570 at Barclays
- IDEXX Laboratories Reports Robust Q3 2024 Performance
- Idexx Laboratories narrows 2024 EPS view to $10.37-$10.53 from $10.31-$10.59
- Idexx Laboratories reports Q3 EPS $2.80, consensus $2.68
- IDXX Upcoming Earnings Report: What to Expect?